Yili Chuanning BiotechnologyLtd Past Earnings Performance
Past criteria checks 5/6
Yili Chuanning BiotechnologyLtd has been growing earnings at an average annual rate of 47.4%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 12.9% per year. Yili Chuanning BiotechnologyLtd's return on equity is 18.1%, and it has net margins of 24.2%.
Key information
47.4%
Earnings growth rate
53.0%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 12.9% |
| Return on equity | 18.1% |
| Net Margin | 24.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Yili Chuanning BiotechnologyLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 5,698 | 1,376 | 189 | 60 |
| 30 Jun 24 | 5,602 | 1,316 | 183 | 60 |
| 31 Mar 24 | 5,077 | 1,118 | 176 | 58 |
| 31 Dec 23 | 4,823 | 941 | 172 | 55 |
| 30 Sep 23 | 4,462 | 719 | 70 | 48 |
| 30 Jun 23 | 4,254 | 565 | 84 | 41 |
| 31 Mar 23 | 4,093 | 486 | 135 | 39 |
| 01 Jan 23 | 3,821 | 412 | 170 | 35 |
| 30 Sep 22 | 3,634 | 272 | 350 | 59 |
| 31 Mar 22 | 3,345 | 154 | 171 | 35 |
| 01 Jan 22 | 3,232 | 111 | 129 | 33 |
| 31 Dec 20 | 3,649 | 229 | 123 | 25 |
| 31 Dec 19 | 3,143 | 91 | 178 | 18 |
| 31 Dec 18 | 3,349 | 390 | 123 | 5 |
Quality Earnings: 301301 has high quality earnings.
Growing Profit Margin: 301301's current net profit margins (24.2%) are higher than last year (16.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301301's earnings have grown significantly by 47.4% per year over the past 5 years.
Accelerating Growth: 301301's earnings growth over the past year (91.3%) exceeds its 5-year average (47.4% per year).
Earnings vs Industry: 301301 earnings growth over the past year (91.3%) exceeded the Biotechs industry 0.08%.
Return on Equity
High ROE: 301301's Return on Equity (18.1%) is considered low.